Allergy, Asthma & Clinical Immunology (Feb 2022)

The use of dupilumab in severe atopic dermatitis during pregnancy: a case report

  • Nabeel H. Akhtar,
  • Touraj Khosravi-Hafshejani,
  • Daud Akhtar,
  • Gurbir Dhadwal,
  • Amin Kanani

DOI
https://doi.org/10.1186/s13223-022-00650-w
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 3

Abstract

Read online

Abstract Background Atopic dermatitis is a common chronic skin disease that can occur in pregnancy. Current treatments include topical and systemic glucocorticoids and cyclosporine. Presently, the only biologic approved for atopic dermatitis is dupilumab with limited data available regarding its safety profile in pregnancy. Case presentation We report a case of severe atopic dermatitis treated safely with dupilumab with no adverse maternal or fetal outcomes and resolution of atopic dermatitis postpartum in the absence of maintenance dupilumab therapy. Conclusion Here we demonstrate the safe use of dupilumab in pregnancy. Further research is needed to elucidate the role of dupilumab in the management of atopic dermatitis during pregnancy.

Keywords